Phase 3 Trial Evaluating an Intracanalicular Dexamethasone Insert (0.4 mg) for the Treatment of Patients with Allergic Conjunctivitis | ASCRS
Phase 3 Trial Evaluating an Intracanalicular Dexamethasone Insert (0.4 mg) for the Treatment of Patients with Allergic Conjunctivitis
May 2020
Meeting: 2020 Virtual Annual Meeting
Session: SPS-111 Cataract Surgery - Medications
Authors: Kenneth R. Kenyon, MD, Eugene McLaurin MD, Erik Anderson MD, Ravi Patel MD, John Meyer MD, Michael Goldstein MBA, MD, Steven Silverstein MD, FACS
This content is only available for ASCRS Members

This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.

To evaluate the safety and efficacy of DEXTENZA (DEX), a resorbable, sustained-release intracanalicular insert delivering a 0.4 mg hands-free, tapered dose of dexamethasone over 30 days for the treatment of allergic conjunctivitis using a modified Conjunctival Allergen Challenge (CAC) Model.

A multi-center, randomized, prospective, double-masked, vehicle-controlled Phase 3 study was conducted using multiple CAC challenges. DEX or placebo vehicle (PV) was inserted bilaterally on Day 1 in subjects (N=96) after confirmation of positive allergic reaction. Ocular itching was evaluated at 3, 5, and 7 mins post-CAC at Day 8 (8 hours post Visit 6a, 7 days post-insertion) as the primary study endpoint. Other secondary efficacy measures include ocular itching (other time points), other ocular and non-ocular symptoms post-CAC at Days 7, 8, 14, 15. Safety assessments included adverse event (AE) collection, visual acuity, slit lamp, punctum exam, intraocular pressure and fundoscopy.

For the primary endpoint, DEX was statistically significantly superior for lowering mean ocular itch scores compared with PV at all time points (P<0.0001). Difference in ocular itching scores favored DEX over PV: 0.86 units at 3 min, 0.98 units at 5 min and 0.96 units at 7 min. For secondary endpoints at all other visits, subjects treated with DEX did better than PV for ocular itching scores post-CAC for all time points (P<0.05 at all visits except Visit 5, 3 minutes). These data are consistent with prior Phase 2 and Phase 3A studies. There were no serious AEs (ocular or non-ocular) and no subjects required rescue. There were no subjects with elevated IOP.

The primary endpoint of the trial was successfully met; DEXTENZA provided a sustained reduction in ocular itching, demonstrating promise as a potential hands-free steroid alternative for patients with allergic conjunctivitis. DEXTENZA was generally safe and well-tolerated in this study.
View More Presentations from this Session

This presentation is from the session "SPS-111 Cataract Surgery - Medications" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.